Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>IMS</strong> COM PANY PRO FILES NOVARTIS SUBSIDIARY LISTING<br />
vel op ment: Joaquin Palacio; Gen eral Con tact:<br />
Ma rina Asarsa<br />
Sub sid iary of: Novartis, Swit zer land (100%)<br />
Phar ma ceu ti cal Sales: US$ 75-80 mil lion<br />
Prod ucts (% of Sales by Lead ing 5): 60-65%<br />
Ther a peu tic Classes (% of Sales by Lead ing<br />
5): 75-80%<br />
Dose Forms (% of Sales by Lead ing 5):<br />
85-90%<br />
Prin ci pal Prod ucts:<br />
VENORUTON (var i cose ther apy sys temic; var i -<br />
cose ther apy top i cal)<br />
CAL CIUM SANDOZ D (cal cium prod uct)<br />
IDALPREM (tran quil izer)<br />
EMPORTAL (lax a tive)<br />
CAL CIUM SANDOZ (cal cium prod uct)<br />
Ther a peu tic Range:<br />
antivaricosis/antihemorrhoidal prep a ra tions<br />
28%<br />
min eral sup ple ments 22%<br />
CNS drugs other 11%<br />
psycholeptics 8%<br />
lax a tives 8%<br />
Lead ing Dose Forms:<br />
pow ders/gran ules 37%<br />
tab lets 33%<br />
oint ments 7%<br />
spe cial solid forms 6%<br />
med i cal dress ings 5%<br />
SANDOZ<br />
Full Name: Sandoz Farmaceutica S.A.<br />
Street Ad dress: Centro Empresarial Osa Mayor,<br />
Av/Osa Mayor no 4, Area B, 28023 Aravaca / Ma -<br />
drid<br />
Tel: +34 93 548 95 71<br />
Fax: +34 93 306 46 29<br />
Email: sandoz.es@gx.novartis.com<br />
Home Page: www.es.sandoz.com<br />
Sub sid iary of: Novartis, Swit zer land (100%)<br />
Phar ma ceu ti cal Sales: US$ 65-70 mil lion<br />
Prod ucts (% of Sales by Lead ing 5): 35-40%<br />
Ther a peu tic Classes (% of Sales by Lead ing<br />
5): 60-65%<br />
Dose Forms (% of Sales by Lead ing 5):<br />
95-100%<br />
Prin ci pal Prod ucts:<br />
METFORMINA SANDOZ (antidiabetic oral)<br />
AMOXI CLAV SAN EFG (pen i cil lin broad spec trum)<br />
OMEPRAZOL SAND EFG (antiulcerant)<br />
AMOXICILINA SANDOZ (pen i cil lin broad spec -<br />
trum)<br />
SIMVASTATINA SANDO (cho les terol/triglyceride<br />
reg u lat ing prep a ra tion)<br />
Ther a peu tic Range:<br />
antibacterials sys temic 25%<br />
drugs used in di a be tes 15%<br />
renin-an gio ten sin sys tem agents 10%<br />
ant ac ids/antiflatulents/antiulcerants 8%<br />
lipid-reg u lat ing/antiatheroma prep a ra tions 7%<br />
Lead ing Dose Forms:<br />
tab lets 36%<br />
coated tab lets 36%<br />
cap sules 14%<br />
vi als 7%<br />
liq uids 4%<br />
SWEDEN<br />
CIBA VI SION<br />
Full Name: CIBA Vi sion Nordic AB<br />
Street Ad dress: Datavagen 24, S-436 32 Askim<br />
/ Goteborg<br />
Tel: +46 31 72 26 600<br />
Fax: +46 31 28 68 43<br />
Home Page: www.cvnordic.com<br />
Sub sid iary of: Novartis, Swit zer land (100%)<br />
NOVARTIS<br />
Full Name: Novartis Sverige AB<br />
Postal Ad dress: Box 1150, S-183 11 Taby /<br />
Stock holm<br />
Street Ad dress: Kemistvagen 1 B, S-183 34<br />
Taby/Stock holm<br />
Tel: +46 8 732 32 00<br />
Fax: +46 8 732 32 01<br />
Home Page: www.novartis.se<br />
De scrip tion: Pro moter, sales/detailer. Prod uct<br />
ranges in clude: phar ma ceu ti cal prod ucts<br />
(branded, pre scrip tion, non-pre scrip tion), di -<br />
etetic/nu tri tional prod ucts, vet er i nary<br />
pharmaceuticals. Es tab lished 1997. 230 phar ma -<br />
ceu ti cal em ploy ees in 2007. Di vi sions in clude:<br />
Novartis Con sumer Health. Con sumer Health;<br />
Animal Health; Pharmaceuticals.<br />
Rep re sen ta tives/De tail ers (Pharm, Num -<br />
ber): 21-50 (2007)<br />
Con tacts (Pharm): Chair man: Dagmar Rosa<br />
Bjorkesson; Com mer cial Op er a tions: Dagmar<br />
Rosa Bjorkesson; Mar ket Re search: Karin Bulow;<br />
Gen eral Con tact: An ders Karnell<br />
Sub sid iary of: Novartis, Swit zer land (100%)<br />
Phar ma ceu ti cal Sales: US$ 140-150 mil lion<br />
Prod ucts (% of Sales by Lead ing 5): 45-50%<br />
© 2009 <strong>IMS</strong> Health In cor po rated or its af fil i ates Page 210
Change language